Vikhanskaya evaluated the effect of six TP53 hotspot mutations (R175H, G245S, R248W, R249S, R273H, and R282W), in conjunction with the codon 72 polymorphism, on various anticancer drugs, either alone or in combination in laboratory generated isogenic lung cancer cell lines (33). This evidence concerns the gene TP53 and lung carcinoma.